United States · FDA National Drug Code directory

PERTZYE

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
59767-016_2ae80639-0555-49c6-bae7-00f43983e614
Product NDC
59767-016
Form
CAPSULE, DELAYED RELEASE
Composition / generic term
pancrelipase
Labeler
Digestive Care, Inc.
Marketing category
BLA
Marketing start / end (source format)
20120517
Source listing expiry
20261231

Source-listed ingredients

  • PANCRELIPASE LIPASE — 16000 [USP'U]/1
  • PANCRELIPASE AMYLASE — 60500 [USP'U]/1
  • PANCRELIPASE PROTEASE — 57500 [USP'U]/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 20 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-016-00) · 59767-016-00
  • 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-016-01) · 59767-016-01
  • 250 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-016-02) · 59767-016-02
  • 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-016-99) · 59767-016-99

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →